ClinicalTrials.gg
TerminatedNCT05188209Updated Sep 9, 2026

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

A Phase 2 interventional study of MRG003 in Advanced or Metastatic Gastric Cancer and Advanced or Metastatic Gastroesophageal Junction Carcinoma, sponsored by Lepu Biopharma Co., Ltd.. Terminated at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated due to sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Enrollment
863rd of 881
6 · median 87
Started
2021
with 96 others
Phase 2
323 of 1,184
133 open now
Registered
577th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 863rd largest by enrollment of the 881 interventional ones that give a count, is one of 97 that started in 2021, is one of 323 in phase 2, and was the 577th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally advanced or metastatic gastric cancer.

Read the detailed description

Approximately 6054 patients will be enrolled to evaluate the safety and preliminarily efficacy of MRG003. Patients will receive 2.0 mg/kg dose of MRG003 intravenously every 3 weeks (Q3W) and may receive up to 24 months of MRG003 if there is evidence of clinical benefit to the patients.

03

Conditions studied

  • Advanced or Metastatic Gastric Cancer
  • Advanced or Metastatic Gastroesophageal Junction Carcinoma

Browse trials for

Keywords

  • MRG003
  • Antibody Drug Conjugate (ADC)
  • Gastric Cancer
  • EGFR-positive, HER2-negative
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - Willing to sign the ICF and follow the requirements specified in the protocol.
  • Age: 18-75 years (including 18 and 75), both genders.
  • Expected survival time≥3 months.
  • Patients with confirmed inoperable locally advanced or gastric adenocarcinoma.
  • Tumor tissue must be EGFR positive and negative.
  • Patients must have according to the (RECIST v1.1).
  • performance score 0 or 1.
  • Organ functions and coagulation function must meet the basic requirements.
  • No severe cardiac dysfunction with (LVEF) ≥ 50%.
  • Serum or urine pregnancy test negative within 7 days before the first dose of drug.
  • Patients with must use effective during the treatment and for 6 months after the last dose of treatment.

Exclusion criteria

Exclusion Criteria:

  • - Squamous cell carcinoma, carcinoid, neuroendocrine carcinoma, undifferentiated carcinoma, or other gastric cancers,or adenocarcinoma with other pathological components that cannot be classified, or adenocarcin oma accompanied by other pathological components.
  • History of to any component of the study drug or to other EGFR-targeting agents.
  • Antitumor biological therapy or immunotherapy, targeted small molecule therapy and have history of systemic chemotherapy within 4 weeks before the first administration of the drug, or major surgery. Traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine formula with anti-tumor effect should not be used within 2 weeks before the first administration.
  • Potent inhibitors or inducers are in use and cannot be discontinued.
  • Known active .
  • Uncontrolled pleural effusion, pericardial effusion or recurrent ascites.
  • Patients with intestinal obstruction requiring treatment were excluded.
  • Residual toxicity reactions caused by previous anti-tumor treatment or abnormal values of laboratory tests higher than grade 1 ( v5.0).

Peripheral neuropathy ≥ Grade 2 (NCICTCAE version 5.0).

  • Uncontrolled or poorly controlled hypertension.
  • Uncontrolled or poorly controlled heart disease.
  • Known active or C.
  • Active bacterial, viral, fungal, rickettsia, or parasitic infections that require systemic anti-infective treatment.
  • Known history of .
  • History of ophthalmologic abnormalities
  • History of severe skin disease
  • Moderate to severe dyspnea at rest caused by advanced cancer or its complications, or severe primary lung disease, oxygen saturation \< 93% in non-oxygen state, or history of any interstitial lung disease or interstitial lung disease (ILD) requiring oral or intravenous or non-infectious pneumonia.
  • Patients with a history of active bleeding, coagulopathy, or receiving coumarin anticoagulation therapy.
  • History of pulmonary embolism or deep vein thrombosis within 6 months before the first administration of the investigational drug.
  • Patients with a history of active bleeding, coagulopathy, or receiving coumarin anticoagulation therapy.

Decompensated cirrhosis of class B, C

  • Complicated with severe, uncontrolled infection or known (HIV) infection, or diagnosed as acquired immunodeficiency syndrome (AIDS); or uncontrolled disease; or history of allogeneic tissue/organ transplantation, stem cell or bone marrow transplantation, or solid organ transplantation.
  • Vaccination of within 30 days before the first administration of the study drug. Inactivated seasonal influenza vaccine or approved COVID-19 vaccine is allowed.
  • Uncontrolled intercurrent illness
  • Patients requiring parenteral nutrition within 4 weeks
  • Women who are lactating or pregnant.
  • Other conditions that in the clinical judgement of the investigator make the patient not suitable for participation in this study.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    MRG003

    On the first day of every 3 weeks, MRG003 will be administered via intravenous infusion at 2.0 mg/kg calculated based on the actual body weight

    Drug: MRG003

Interventions

  • DrugMRG003

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Independent Review Committee (IRC)

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by Independent Review Committee (IRC) according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  2. Adverse Events (AEs)

    Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.

    Time frame: Baseline to 30(for AE) and 45(for SAE) days after the last dose of study treatment

Secondary outcomes

  1. Objective Response Rate (ORR) by Investigator

    ORR is defined as the proportions of patients with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to RECIST v1.1.

    Time frame: Baseline to study completion (up to 24 months)

  2. Progression Free Survival (PFS)

    PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  3. Duration of Response (DoR)

    DOR is defined as the duration from the initial recording of objective disease response to the first onset of tumor progression, or death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  4. Disease Control Rate (DCR)

    DCR is defined as the proportions of patients achieving CR, PR, and stable disease (SD) after treatment.

    Time frame: Baseline to study completion (up to 24 months)

  5. Overall Survival (OS)

    OS is defined as the duration from the start of treatment to death of any cause.

    Time frame: Baseline to study completion (up to 24 months)

  6. PK parameter for MRG003: (Cmax)

    Maximum observed plasma concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  7. PK parameter for MRG003: (AUClast)

    Area under the curve up to the last validated measurable plasma concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  8. PK parameter for total antibody (TAb): Cmax

    Maximum observed plasma concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  9. PK parameter for TAb: AUClast

    Area under the curve up to the last validated measurable plasma concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  10. PK parameter for Monomethyl Auristatin E (MMAE): Cmax

    Maximum observed plasma concentration.

    Time frame: Baseline to 30 days after the last dose of study treatment

  11. PK parameter for MMAE: AUClast

    Area under the curve up to the last validated measurable plasma concentration

    Time frame: Baseline to 30 days after the last dose of study treatment

  12. The proportion of patients with positive of anti-drug antibody (ADA)

    The proportion of patients with positive ADA immunogenicity results.

    Time frame: Baseline to 30 days after the last dose of study treatment

07

Study locations

5 sites
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Henan Tumor Hospital
    Zhengzhou, Henan, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Oct 2022, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2022
First posted
Jan 12, 2022
StartActual
Dec 31, 2021
Primary completionActual
Oct 12, 2022
CompletionActual
Oct 12, 2022
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05188209
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2022
Start date
Dec 31, 2021
Primary completion
Oct 12, 2022
Completion
Oct 12, 2022
Last update
Sep 9, 2026

Study contacts

Aiping Zhou, Doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug vedotin

Start the discussion